San Francisco, United States
Shasqi, founded in 2015, is at the forefront of innovative cancer treatment, leveraging click chemistry, a 2022 Nobel Prize winning technology, to improve cancer drug delivery. Positioned within the Biotechnology, Health Care, and Pharmaceutical sectors, Shasqi's mission is to minimize the toxicity of cancer treatments while maximizing their effectiveness.
Its proprietary CAPAC® platform uniquely targets tumor sites by utilizing a click chemistry reaction that selectively delivers drug payloads, thereby sparing healthy cells. This pioneering approach has positioned Shasqi as the first company to implement click chemistry in human treatments, demonstrating a significant therapeutic advancement.
Located in the United States, Shasqi's last financing milestone was a $50.00M Series B round on 01 November 2021, led by notable investor Bill Rieflin. Given its groundbreaking technology and strategic industry positioning, Shasqi represents a compelling opportunity in oncology therapeutics.
